231 related articles for article (PubMed ID: 16098249)
41. Oral fluoropyrimidines: a closer look at their toxicities.
Macdonald JS
Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
[TBL] [Abstract][Full Text] [Related]
42. Capecitabine in gastric cancer.
Okines A; Chau I; Cunningham D
Drugs Today (Barc); 2008 Aug; 44(8):629-40. PubMed ID: 18846273
[TBL] [Abstract][Full Text] [Related]
43. [Capecitabine in colorectal carcinoma: news from ASCO 2008]].
Longo F; Mansueto G
Tumori; 2008; 94(4):suppl 15-23. PubMed ID: 18822712
[No Abstract] [Full Text] [Related]
44. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review.
Saif MW; Hashmi S; Zelterman D; Almhanna K; Kim R
Int J Colorectal Dis; 2008 Feb; 23(2):139-45. PubMed ID: 17909820
[TBL] [Abstract][Full Text] [Related]
45. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
Glen H; Cassidy J
Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
[TBL] [Abstract][Full Text] [Related]
46. Capecitabine: fulfilling the promise of oral chemotherapy.
Hwang JJ; Marshall JL
Expert Opin Pharmacother; 2002 Jun; 3(6):733-43. PubMed ID: 12036413
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
[TBL] [Abstract][Full Text] [Related]
48. Capecitabine: an overview of the side effects and their management.
Saif MW; Katirtzoglou NA; Syrigos KN
Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
[TBL] [Abstract][Full Text] [Related]
49. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
50. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
Chiara S; Nobile MT; Vincenti M; Lionetto R; Gozza A; Barzacchi MC; Sanguineti O; Repetto L; Rosso R
Cancer Chemother Pharmacol; 1998; 42(4):336-40. PubMed ID: 9744780
[TBL] [Abstract][Full Text] [Related]
51. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
Jansman FG; Postma MJ; van Hartskamp D; Willemse PH; Brouwers JR
Clin Ther; 2004 Apr; 26(4):579-89. PubMed ID: 15189755
[TBL] [Abstract][Full Text] [Related]
52. Role of oral chemotherapy in colorectal cancer.
Donehower RC
Oncology (Williston Park); 2000 Nov; 14(11A):243-5. PubMed ID: 11195416
[TBL] [Abstract][Full Text] [Related]
53. Safety of capecitabine: a review.
Mikhail SE; Sun JF; Marshall JL
Expert Opin Drug Saf; 2010 Sep; 9(5):831-41. PubMed ID: 20722491
[TBL] [Abstract][Full Text] [Related]
54. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
[TBL] [Abstract][Full Text] [Related]
55. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
[TBL] [Abstract][Full Text] [Related]
56. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
Ajani J
Cancer; 2006 Jul; 107(2):221-31. PubMed ID: 16770784
[TBL] [Abstract][Full Text] [Related]
57. Potential of Xeloda in colorectal cancer and other solid tumors.
Cassidy J
Oncology; 1999 Jul; 57 Suppl 1():27-32. PubMed ID: 10436414
[TBL] [Abstract][Full Text] [Related]
58. Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
Prescrire Int; 2002 Apr; 11(58):44-7. PubMed ID: 11987311
[TBL] [Abstract][Full Text] [Related]
59. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
[TBL] [Abstract][Full Text] [Related]
60. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]